Patritumab: Phase III discontinued

Daiichi discontinued the double-blind, placebo-controlled, international Phase III HER3-Lung trial of IV patritumab after an IDMC concluded the study’s first part assessing PFS did not meet the predefined efficacy criteria. The IDMC did not identify any safety issues. The company said a Phase II trial of patritumab in head and neck cancer remains unchanged and ongoing. ...